Compare Ginkgo Bioworks Holdings Inc (DNA) vs Hut 8 Corp (HUT) Price & Performance

Ginkgo Bioworks (DNA) trades at $12.84, up 11.94% in the last session. The stock shows a bullish technical signal with strong moving average support, though oscillators are neutral. Fundamentally, the company reported a net loss of $312.76 million in 2025 on $170.16 million revenue, with a negative net margin of 219.6%. Recent news includes a $17.5 million ARPA-H subcontract for RNA medicine manufacturing, highlighting strategic growth initiatives despite financial challenges.

Outlook remains speculative with high risk. The buy/hold/sell analyst split is nearly even, reflecting uncertainty. Significant cash burn and persistent losses pose substantial risks, but partnerships and government contracts offer potential catalysts. Investors should weigh the company's long-term biotechnology prospects against its current lack of profitability and negative cash flow.

Hut 8 Corp. (HUT) trades at $81.20, down 9.07% amid a bearish technical signal. The company reported a net loss of $226.15 million in 2025 despite revenue of $235.12 million, with negative cash flow from operations. Recent news highlights a $1.07 billion credit facility and strong analyst buy ratings, with a consensus price target of $162.69 suggesting significant upside potential.

The outlook is mixed: robust analyst support and AI infrastructure growth opportunities contrast with persistent losses and high valuation ratios. Key risks include execution on profitability and sensitivity to sector sentiment. The stock's near-term direction hinges on earnings improvement and contract execution.